Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Carefusion Corporation is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action, which is being handled by a single distinct examiner. This indicates a singular focus in the current prosecution cycle, as the entire pending workload is concentrated in a single point of review. For a patent practitioner, this means that the immediate results for the portfolio depend on one specific interaction within the USPTO.
The busiest examiner for this company is PEEBLES, KATHERINE, who is responsible for 1 busiest examiner pending action. Since there is only a single pending office action in total, this individual manages the whole of the company's active office action responses. This concentration in Biotechnology & Pharmaceuticals suggests that the company is not currently managing a high volume of simultaneous disputes or reviews across different examiners, which may allow for more dedicated attention to this specific case.
Navigating prosecution with a single distinct art unit requires a highly tailored approach to the standards of that specific group. The lack of diversity in examiners for the 1 pending office action means there are no internal benchmarks for comparison within the portfolio. Practitioners must rely on the specific feedback from PEEBLES, KATHERINE to guide the strategy for the Biotechnology & Pharmaceuticals applications, ensuring that the response aligns with the examiner's particular preferences.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEEBLES, KATHERINE | 1 | 35.5% | +48.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17180539 | SYSTEMS AND METHODS FOR STERILIZING IODOPHOR COMPOSITIONS | PEEBLES, KATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17180539 | SYSTEMS AND METHODS FOR STERILIZING IODOPHOR COMPOSITIONS | PEEBLES, KATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17180539 | SYSTEMS AND METHODS FOR STERILIZING IODOPHOR COMPOSITIONS | PEEBLES, KATHERINE | 1617 | §103§112 | Final Rejection | — | Pending | Feb 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial